Helius Medical Technologies Inc - Ordinary Shares - Class A
HSDT
Get informed when a big investor buys or sells
+ FollowMarket Cap$161.15M
Close$
$-2.15
174.2% downside
Current Fair Value
174.2% downsideOvervalued by 174.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $161.15 Million |
|---|---|
| Enterprise Value | $157.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.85 |
| Beta | 1.07 |
| Outstanding Shares | 78,254,877 |
Return
| Return on Equity | -94.95% |
|---|---|
| Return on Assets | -89.33% |
| Return on Invested Capital | -147.91% |
Valuation & Multiples
| P/E Ratio | -0.09 |
|---|---|
| PEG | -0.04 |
| Price to Sales | - |
| Price to Book Ratio | 1.45 |
| Enterprise Value to Revenue | 13.05 |
| Enterprise Value to EBIT | -0.61 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$2.90 M
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$2.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1770▼ 13.07% |
|---|---|
| Total Calls | 79,100▼ 33.14% |
| Total Puts | 14,000▼ 61.54% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.15%▲ 0.21% |
|---|---|
| Total Invested | $26.02M▼ 1.71% |
| Investors Holding | 45▼ 6.00% |
ESG Score
No data
About Helius Medical Technologies Inc
19 employees
CEO: Philippe Deschamps Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. ...